CSL Ltd Annual Report 2021

What we draw on Value we create A healthier more productive society Protecting global health and the wellbeing of individuals, families, businesses and communities from life-threatening and/or complications resulting from influenza. Saving and/or improving the quality of life of hundreds and thousands of people with rare and serious diseases. Sustainable financial growth Delivering consistent, profitable and responsible growth for our investors, which fuels innovation and development. Social and economic opportunity Enabling hundreds of thousands of people to benefit from opportunity created by growing along with us, including employees, suppliers, plasma donors and research partners. Unmet need Opportunities to improve and protect the quality of life of patients in therapy areas we treat. Our people 25,000+ people with diverse skills that are driven by our purpose and values. Natural resources Includes: plasma donations for rare and serious diseases; influenza virus strains for product manufacture; and environmental inputs such as water and energy. Financial resources Cash, equity and debt for future growth. Physical assets Plasma centres to collect rawmaterial, manufacturing facilities for our products, warehouses, offices for our people and laboratories for our scientists. Collaborators and business partners Accessing and sharing intellectual know how to develop and innovate our products . How we create value CSL’s ultimate goal is to deliver value through fulfilling unmet patient needs and protecting public health. With patients and public health at the core of our focus, we also strive to deliver sustainable financial growth for our shareholders and other stakeholders who rely on our operations for economic and social prosperity. CSL Limited Annual Report 2020/21 16 4 Our Strategy and Performance